You are here: Industry Insights > Zeposia

News List

Bristol Myers Squibb Receives European Commission Approval of Zeposia for Ulcerative Colitis AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb today announced that the European Commission has granted a Marketing Authorization for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response...
EC approve Zeposia® to treat ulcerative colitis EuropeanPharmaceuticalReview
November 29, 2021
The European Commission (EC) has has granted a marketing authorisation for Zeposia® (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC)...
U.S. FDA Approves an Oral Treatment for Adults with Ulcerative Colitis americanpharmaceuticalreview
June 02, 2021
Bristol Myers Squibb announced that the U.S. FDA approved Zeposia® (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Once daily multiple sclerosis treatment approved for use in Scotland europeanpharmaceuticalreview
February 10, 2021
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
SMC approves funding for four new medicines on the NHS pharmatimes
February 09, 2021
In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland.
NICE no for BMS’ multiple sclerosis drug Zeposia pharmatimes
January 25, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).
Bristol Myers Squibb presents data from True North trial of Zeposia (ozanimod) for ulcerative colitis expresspharma
October 12, 2020
Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus placebo at Week 10 and Week 52.
Bristol Myers Squibb announces positive topline results from True North trial evaluating Zeposia in pharmaceutical-business-review
June 05, 2020
Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.
Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease pharmaceutical-business-review
June 01, 2020
Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis europeanpharmaceuticalreview
March 31, 2020
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.

Previous page 1 2 Next page